News National MS Society, Corrona to Launch Registry Comparing Approved MS Therapies National MS Society, Corrona to Launch Registry Comparing Approved MS Therapies by Patricia Silva, PhD | November 6, 2017 Share this article: Share article via email Copy article link The National Multiple Sclerosis SocietyĀ (NMSS) has officially announced its collaboration with Corrona on the launch of the Corrona Multiple Sclerosis Registry to compare the safety and effectiveness of approved therapies in multiple sclerosis (MS). Corrona, based in Cambridge, Massachusetts, conducts observational cohort studies, offering analytic expertise for longitudinal clinical data, patient-reported measures and others to compare effectiveness, post-market safety reporting and commercial applications. Under the accord, a national observational registry will collect and analyze longitudinal outcomes associated with several MS therapies. The registry, which has already enrolled its first patient, eventually plans to recruit 5,000 people with MS. Today, MS is managed through disease-modifying treatments that prevent relapses and exacerbations, slowing its progression. Since the U.S. Food and Drug Administration approved the first MSĀ disease-modifying treatment in 1993, patients have seen an “an unprecedented leap forward” in the number and variety of medications available, Daniel Kantor, founding president of the Medical Partnerships 4 MS, said inĀ a press release.Ā “But MS research in the U.S. lags behind other fields in collecting reliable real-world data to compare the safety and effectiveness” of these therapies, he said. The registry will collect data from patients and their treating neurologists through questionnaires, and includes physician assessments and patient-reported outcomes. Along with the NMSS and other partners, Corronaās team of biostatisticians and epidemiologists will study the comparative safety and efficacy of approved MS therapies. “Identifying the optimal treatment strategy is a critical issue for people with MS and their healthcare providers,” said Bruce Bebo, executive vice president of research at NMSS. “The collaboration with Corrona on the MS registry addresses this challenge and furthers our goal of ensuring that people with MS have [the] information, tools and resources to live their best lives.” This is Corronaās sixth registry, following studies in rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and others. “Corrona is honored to partner with the National MS Society and U.S. neurologists to create a national MS registry that can help guide treatment decisions for patients based on real-word comparative effectiveness and safety analyses,ā said Jeff Greenberg, chief scientific officer of Corrona. To learn more about the Corrona MS Registry and enrollment details, contact [email protected] or call (508) 408-5398. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags efficacy, National MS Society, registry, safety, therapies
April 26, 2024 News by Margarida Maia, PhD Employment, income drop steadily over 2 decades after onset of MS
April 26, 2024 News by Marisa Wexler, MS Machine learning model predicts CIS to MS conversion risk: Study
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression